KRISTA CARVER

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Medication Affordability and Patent Integrity Act (S. 2658); Biopharmaceutical policy issues; Skinny Labels, Big Savings Act (S. 43/H.R. 6485).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658); Biopharmaceutical policy issues.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Medication Affordability and Patent Integrity Act (S. 2658); Biopharmaceutical policy issues; Skinny Labels, Big Savings Act (S. 43/H.R. 6485).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658); Biopharmaceutical policy issues.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Fast-tracking Approval for Innovative Rare disease therapies (FAIR) Act (H.R. 7953); Ensuring Timely Access to Generics Act of 2025 (S. 3014); Stop STALLING Act (S. 1095); Food & Drug Administration Fiscal Year 2027 Legislative Proposals; Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646); Medication Affordability and Patent Integrity Act (S. 2658); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Expedited Access to Biosimilars Act (S. 1414); Clinical trial regulation; Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); Securing Innovation and Research from Adversaries (discussion draft); amendments to the National Childhood Vaccine Injury Act of 1986 and the Vaccine Injury Compensation Program; Destruction of Hazardous Imports Act (H.R. 2715); potential amendments to drug country of origin labeling requirements (discussion draft).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Medication Affordability and Patent Integrity Act (S. 2658); Biopharmaceutical policy issues; Skinny Labels, Big Savings Act (S. 43/H.R. 6485).

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Proposed Rule, 91 Fed. Reg. 36236; Medication Affordability and Patent Integrity (MAPIA) Act (S. 2658); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Expedited Access to Biosimilars Act (S. 1414/ H.R.9661); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); Clinical trial regulation; Community Health Center Clinical Trial Grant Program discussion draft; Alex and Jacis Law discussion draft; Untitled discussion draft on clinical trial regulation (no bill number); Untitled discussion draft on generic drugs intended for use with a device (no bill number); Food & Drug Administration Fiscal Year 2027 Legislative Proposals (no bill number); Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act, (S.3788 / H.R.8269); draft legislation relating to potential improvements the National Childhood Vaccine Injury Act and the Vaccine Injury Compensation Program; American Biotechnology Act, Senate Amendment 6334 to S. 4784, National Defense Authorization Act (NDAA) for Fiscal Year 2027; CARES Act (P.L. 116-136) reporting issues.

Biosimilars Access and Affordability Act (S. 5459); Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Eliminating Thickets to Increase Competition (ETHIC) Act (S. 2276/H.R. 3269); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954/H.R. 5526); CLEAR Act (H.R.7140); Artificial Intelligence-Ready Data Act (S.4098); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); Drug Competition Enhancement Act (S.1040); America's Living Library Project Bill (S. 4023); Securing Essential Components for U.S. Readiness in Essential Pharmaceuticals (SECURE Rx) Act of 2026 (discussion draft); improvements to the National Childhood Vaccine Injury Act of 1986; Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act (S. 3788).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843).

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843).

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).

Biopharmaceutical innovation and intellectual property policy issues; patent subject matter; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Skinny Labels, Big Savings Act (S. 43); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).

Biopharmaceutical innovation and intellectual property policy issues; patent subject matter; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Skinny Labels, Big Savings Act (S. 43); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Biopharmaceutical innovation and intellectual property policy issues; Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); induced infringement.

Biopharmaceutical innovation and intellectual property policy issues; patent subject matter; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Skinny Labels, Big Savings Act (S. 43); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (no bill number); REMEDY Act (S. 2620); FDA Modernization Act 3.0 (S. 355 / H.R. 2821); issues related to reauthorization of the Prescription Drug User Fee Act (no bill); proposed amendment to the National Defense Authorization Act for Fiscal Year 2026 (S.Amdt.3236 to S.2296); issues related to vaccine access (no bill); Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Medication Affordability and Patent Integrity Act (S. 2658 / no House bill); Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954, HR 5526); Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 (S.2256); conditional approval; orphan-drug exclusivity; FDA reform.

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843).

FDA Modernization Act 3.0 (S. 355 / H.R. 2821); Expedited Access to Biosimilars Act (S. 1414); Orphan-drug exclusivity; draft Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act (no bill number); Clinical Trials; Reciprocal approvals; Skinny Labels, Big Savings Act (S. 43/H.R. 6485); Increasing Transparency in Generic Drug Applications Act (S. 1302/H.R. 1843); BIOSECURE Act, Sec. 851 of the Fiscal Year (FY) 2026 National Defense Authorization Act (NDAA)(S. 1071/H.R. 3838); Potential legislation relating to the Vaccine Injury Compensation Program and other issues affecting vaccines.

Biopharmaceutical innovation and intellectual property policy issues; patent subject matter; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Skinny Labels, Big Savings Act (S. 43); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).

Issues related to biopharmaceutical innovation and intellectual property (no bill); issues related to intellectual property and Bayh-Dole in the Genomic Data Protection Act (S. 863 / no House bill); induced infringement.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Give Kids a Chance Act of 2025 (H.R. 1262/S. 932); Stop STALLING Act (S. 1095); approval pathways; S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; biosimilar testing; S. 1041, A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Innovation in Pediatric Drugs Act of 2025 (S. 705); biosimilar policy issues; Skinny Labels, Big Savings Act (S. 43).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilars Access and Affordability Act (S. 5459); Preserve Access to Affordable Generics and Biosimilars Act (S. 1096); EPIC Act of 2025 (S. 832); H.R.1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Increasing Transparency in Generic Drug Applications Act (S.1302); Stop STALLING Act (S. 1095); S. 1040, A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; Interagency Patent Coordination and Improvement Act of 2025 (S. 1097); approval pathways; Expedited Access to Biosimilars Act (S. 1414); Biosimilar Red Tape Elimination Act (S. 1954); USFDA-PTO collaboration; FDA reductions in force and FDA reforms; drug supply chain; right to try; ORPHAN Cures Act (H.R. 946); H.R.1 - One Big Beautiful Bill Act; priority review vouchers; Family Vaccine Protection Act (H.R. 3701).

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilar Red Tape Elimination Act (S.2305); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); S.3583/H.R. 6986, A bill to address patent thickets; Medication Affordability and Patent Integrity Act (S.2780); Stop STALLING Act (S. 148); S.5573 - A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products; H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications; Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025 (H.R. 10445); FDA Modernization Act 3.0 (H.R. 7248); Promising Pathway Act (H.R. 3761/S. 1644); BIOSECURE Act (H.R. 7085); Section 851 (Prohibition on Contracting with Covered Entities that Contract with Lobbyists for Chinese Military Companies) of the Fiscal Year 2024 National Defense Authorization bill ((H.R. 5009/S. 4638); Biotechnological Innovation and Opportunity for Competitive Economic Transformation Act of 2024 (BioCompete) ; clinical trial diversity; rare diseases; patent listing; rare pediatric disease priority review vouchers.

Proposed amendments to the Inflation Reduction Act (P.L. 117-169); Biosimilar Red Tape Elimination Act (S.2305); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); S.3583/H.R. 6986, A bill to address patent thickets; Medication Affordability and Patent Integrity Act (S.2780); Stop STALLING Act (S. 148); S.5573 - A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products; H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications; Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025 (H.R. 10445); FDA Modernization Act 3.0 (H.R. 7248); Promising Pathway Act (H.R. 3761/S. 1644); BIOSECURE Act (H.R. 7085); Section 851 (Prohibition on Contracting with Covered Entities that Contract with Lobbyists for Chinese Military Companies) of the Fiscal Year 2024 National Defense Authorization bill ((H.R. 5009/S. 4638); Biotechnological Innovation and Opportunity for Competitive Economic Transformation Act of 2024 (BioCompete) ; clinical trial diversity; rare diseases; patent listing; rare pediatric disease priority review vouchers.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); S.2305 - Biosimilar Red Tape Elimination Act; Promising Pathway Act (S. 1906/H.R.4408); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583 - A bill to address patent thickets; REMEDY Act (S. 1209); Biosecure Act (S. 3558); proposed changes to Vaccine Injury Compensation Program.

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); Biosimilar Red Tape Elimination Act (S. 2305); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583/H.R. 6986, A bill to address patent thickets; REMEDY Act (S. 1209); FDA Modernization Act 3.0 (H.R. 7248); Increasing Transparency in Generic Drug Applications Act (S. 775); Medication Affordability and Patent Integrity Act (S. 2780); Patent listing; Requirements for generic drug-device combination products; priority review vouchers; 3-year exclusivity; Biosecure Act (H.R. 7085, H.R. 8333, S. 3385); Biotechnological Innovation and Opportunity for Competitive Economic Transformation Act of 2024 (BioCompete); Invent Here, Make Here (S. 1956).

Implementation and proposed amendments to the Inflation Reduction Act (P.L. 117-169); Innovation in Pediatric Drugs Act of 2023 (H.R. 6664); Biosimilar Red Tape Elimination Act (S.2305); Give Kids a Chance Act of 2023 (H.R. 3433/S.2897); Affordable Prescriptions for Patients Act of 2023 (S. 150); Induced infringement and generic drug labeling; S.3583/H.R. 6986, A bill to address patent thickets; REMEDY Act (S. 1209); Medication Affordability and Patent Integrity Act (S.2780); rare pediatric disease priority review vouchers; Stop STALLING Act (S. 148); Interagency Patent Coordination and Improvement Act of 2023 (S. 79); Preserve Access to Affordable Generics and Biosimilars Act (S. 142); Bayh-Dole; Biosecure Act (H.R. 7085, H.R. 8333, S. 3385); and The Federal Acquisition Security Council Improvement Act (discussion draft).